Human immunodeficiency virus 1 envelope glycoprotein gp120 glycan shield (2G12 epitope) (HIV-1 gp120 2G12 epitope)

The HIV-1 gp120 glycan shield (2G12 epitope) is a specialized antigenic region on the surface of the Human Immunodeficiency Virus type 1 envelope glycoprotein. This epitope is composed of a dense cluster of host-derived high-mannose N-linked glycans, primarily at positions N332, N339, and N392, which the virus uses to shield its protein surface from the host immune system (PMID: 12970568). Unlike most epitopes, the 2G12 site is recognized by the broadly neutralizing antibody 2G12 through a unique domain-swapped configuration that targets the carbohydrate structure itself rather than the underlying protein (PMID: 14551444). This target is significant in HIV research because it represents a conserved site of vulnerability that can be exploited for the development of vaccines and entry-inhibitor therapies. By binding to this glycan cluster, therapeutic agents can neutralize the virus and prevent it from docking with and infecting CD4+ T cells (PMID: 11160754). Therapeutic challenges include the high degree of glycan heterogeneity across different HIV strains and the ability of the virus to evolve escape mutations that shift glycan positions. Despite these challenges, the 2G12 epitope remains a primary model for understanding how the immune system can overcome the viral glycan shield.

Other names

HIV-1 gp120 high-mannose cluster2G12 glycan epitopegp120 glycan shieldHIV-1 Env glycan cluster

Neutralization of viral entry by binding to high-mannose glycans on gp120, preventing viral attachment and fusion with host cells.